Nuvation Bio posts corporate deck spotlighting IBTROZI launch, oncology pipeline programs

NUVATION BIO INC

NUVATION BIO INC

NUVB

0.00
  • Nuvation Bio highlighted IBTROZI (taletrectinib) as a commercial-stage growth driver in advanced ROS1+ NSCLC, with U.S., Japan, China clearances.
  • U.S. net product revenue reached USD 24.7 million in 2025; quarterly revenue rose to USD 18.5 million in Q1 2026.
  • More than 600 new patient starts were recorded through March 31, 2026; over 50% of new starts were first-line in Q1 2026.
  • Cash, cash equivalents, and marketable securities totaled USD 533.7 million as of March 31, 2026; management expects a path to profitability without additional funding.
  • Pipeline focus includes pivotal SIGMA study enrollment for safusidenib in IDH1-mutant glioma; preclinical Drug-Drug Conjugate candidates remain under evaluation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief on June 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.